開拓藥業(09939.HK)獲批准兩項治療新冠病毒III期臨床試驗
開拓藥業(09939.HK)公布,已獲得國家藥品監督管理局批准,於中國進行普克魯胺片擬用於治療新型冠狀病毒肺炎的兩項III期臨床試驗。
該等III期臨床試驗均為全球多中心臨床試驗(「MRCT」)。其中一項III期臨床試驗(NCT編號:NCT04869228)於中國、巴西、馬來西亞、菲律賓等國家治療輕中度COVID-19男性患者,而另一項III期臨床試驗(NCT編號:NCT05009732)於美國、中國、南美洲(包括巴西)、歐洲及印度等國家治療重症住院COVID-19患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.